Phaseline

Targets › DGAT2

DGAT2 (Diacylglycerol O-acyltransferase 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Immunology; next expected readout Aug 2027.

Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides. (UniProt, Q96PD7)

Open in Phaseline: the race on DGAT2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sagimet BiosciencesDenifanstat
DGAT2 inhibitor
DGAT2Phase 3Acne VulgarisAug 2027

Conditions

Acne Vulgaris (1)

Modalities

small molecule (1)

Companies

Sagimet Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.